RASSF1A基因在胃腺癌和癌前病变中的表达及意义

Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis

BACKGROUND

In recent years, the predictive role of YKL-40 for long-term survival in colorectal cancer patients has been gradually investigated. However, whether it is a reliable and valuable prognostic indicator for patients with colorectal carcinoma has not been verified.

AIM

To identify the prognostic value of serum/plasma concentration of YKL-40 or expression status of YKL-40 in tumor cells in colorectal carcinoma patients.

METHODS

Several electronic databases including the PubMed, EMBASE, Web of Science, CNKI, VIP and WanFang were searched for relevant studies. The hazard ratios (HR) and 95% confidence intervals (CI) were combined and the primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS), respectively. All statistical analysis were conducted by STATA 15.0 software.

RESULTS

A total of nine studies involving 2545 patients were included. The pooled results indicated that YKL-40 was significantly associated with poor OS (HR = 1.80, 95%CI: 1.32-2.45, P < 0.001) and PFS (HR = 1.62, 95%CI: 1.22-2.16, P = 0.001). Subgroup analysis stratified by the treatment, tumor type and source of YKL-40 showed similar results.

CONCLUSION

Elevated serum/plasma concentration of YKL-40 or positive expression in tumor cells was related with worse prognosis of colorectal carcinoma patients. YKL-40 might serve as a novel and reliable indicator for the evaluation of prognosis in colorectal cancer.

Correlation between hMLH1 and RASSF1A expression and prognosis of esophageal carcinoma

AIM: To investigate the expression of human mutL homologue 1 (hMLH1) and Ras association domain family 1A (RASSF1A) in esophageal squamous cell carcinoma (ESCC) and to analyze their prognostic value.

METHODS: The expression of hMLH1 mRNA and RASSF1A protein in 60 specimens of esophageal cancer was detected by in situ hybridization (ISH) and immunohistochemistry, respectively. The relationship of hMLH1 and RASSF1A expression with ESCC prognosis was evaluated using Cox regression model and Kaplan-Meier survival curve analysis.

RESULTS: The positive rates of hMLH1 and RASSF1A expression in esophageal carcinoma were significantly lower than those in normal esophageal tissue (41.67% vs 90.00%, 80.00% vs 100.00%; both P < 0.05). The expression of hMLH1 and RASSF1A was correlated with tumor TNM stage, invasion depth, lymph node metastasis, and tumor size (all P < 0.05), but not with patient's nationality (P > 0.05). The expression of RASSF1A was positively correlated with that of hMLH1 (r = 0.338, P < 0.01). The five-year overall survival rate for all the patients was 35% (21/60). Univariate survival analysis suggested that the five-year survival rate for patients with positive expression of RASSF1A was higher than that for patients with negative expression of RASSF1A though the difference was not significant (P > 0.05). Patients with positive expression of hMLH1 had a significantly higher survival rate compared to those with negative expression of hMLH1 (P < 0.05). Cox multivariate analysis indicated that tumor invasion depth and TNM stage were independent prognostic factors affecting survival of ESCC patients (both P < 0.05).

CONCLUSION: Both hMLH1 and RASSF1A were weakly expressed in ESCC. The expression of hMLH1 and RASSF1A was positively correlated with ESCC progression. Expression of hMLH1 and RASSF1A might be used as a prognostic parameter in ESCC patients.